Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07504796 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Name: ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab — clinical trial record (NCT07504796)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorNYU Langone Health

Started2026-04-13

View on ClinicalTrials.gov ↗

Amendment history

2026-08-20

Study Status, Study Design v2

Phase changed: Phase 4 → Phase 2

2026-04-17

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-05→confirmed 2026-04-13

Study sitesdetails revised at 1 of 1 site

2026-03-26

Original filing

NYU Langone Health

394 trials monitored

See 18 trials at risk

Melanoma

1,020 trials monitored

See 45 trials at risk

The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.

Trial Details

NCT Number	NCT07504796
Lead Sponsor	NYU Langone Health
Conditions	Metastatic Melanoma, Advanced Melanoma
Enrollment	90 participants
Start Date	2026-04-13
Primary Completion	2029-05 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-24